Health Canada consultation on reducing youth access and appeal of vaping products
https://policybase.cma.ca/link/policy14078

POLICY TYPE          Response to consultation
DATE                2019-05-24
TOPICS              Pharmaceuticals, prescribing, cannabis, drugs
Population health, health equity, public health

Documents
Cannabis for Medical Purposes

The Canadian Medical Association (CMA) has always recognized the unique requirements of those individuals suffering from terminal illnesses or chronic diseases for which conventional treatments have not been effective and for whom conventional medical care is not possible. 

There is an urgent need for more evidence in this area. The CMA supports the need for evidence-based information, including information about the potential therapeutic effects of cannabis.

The CMA endorses the following recommendations:

1. Support the advancement of scientific knowledge about the medical use of cannabis. We recommend the establishment of an independent scientific panel to review the literature, assess the efficacy for therapeutic use, monitor and report on the use of cannabis and its products, and review the results of this work periodically.

2. Support the establishment of a national program of research on the therapeutic use of cannabis, including the development of a national research and development strategy, and the establishment of a national research and development fund.

3. Support the establishment of a national licensing system for the therapeutic use of cannabis, including the establishment of a national licensing authority, and the establishment of a national licensing system for the therapeutic use of cannabis.

4. Support the establishment of a national health and safety strategy for the therapeutic use of cannabis, including the establishment of a national health and safety strategy for the therapeutic use of cannabis.

5. Support the establishment of a national education and information strategy for the therapeutic use of cannabis, including the establishment of a national education and information strategy for the therapeutic use of cannabis.
MEDICATION USE AND SENIORS

(UPDATE 2017)

The Canadian Medical Association recommends the following principles for the safe use of medications by seniors:

1. Seniors are a vulnerable population and require special consideration when using medications.
2. Prescriptions should be reviewed for appropriateness, effectiveness, and safety.
3. Over-the-counter medications should be used with caution and under the guidance of a healthcare professional.
4. Regular reviews of medication lists are necessary to identify and address any potential drug interactions.
5. Medication use education is essential for seniors and their caregivers.
6. Seniors should be encouraged to ask questions about their medications and to report any side effects.
7. Health care providers should monitor seniors for adverse drug reactions and adjust medications as needed.
8. Medication adherence programs can improve health outcomes for seniors.

The CMA supports the development of programs to improve medication safety for seniors. These programs should focus on education, awareness, and the identification and implementation of strategies to reduce medication risks.

CMA POLICY

Vision for e-Prescribing: a joint statement by the Canadian Medical Association and the Canadian Pharmacy Association

CMA Policybase - Canadian Medical Association